GSK slams ACCC’s ‘onerous’ compliance program in Voltaren case
The final day of trial in the ACCC’s case over muscle gel Voltaren wrapped up Wednesday with a barrister for GlaxoSmithKline slamming as ‘onerous’ a compliance regime proposed by the consumer watchdog and blasting an injunction as unnecessary for a problem the pharmaceutical giant ‘inherited’ from Novartis.